Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Blocklisting Interim Review

6 Feb 2015 09:31

RNS Number : 2593E
ABCAM Plc
06 February 2015
 



For immediate release

6 February 2015

ABCAM PLC

("Abcam" or "the Company")

 

Block Admission Return

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Abcam plc

Name of scheme:

1. Abcam EMI Scheme

2. Abcam SAYE Scheme

3. Abcam 2005 Share Option Scheme

4. Abcam Share Incentive Plan

5. Abcam Company Share Option Plan

6. Abcam Long Term Incentive Plan

7. Annual Bonus Plan

Period of return:

From:

6 August 2014

To:

5 February 2015

Balance of unallotted securities under scheme(s) from previous return:

1. 568,815

2. 31,405

3. 2,775,259

4. 464,586

5. 727,253

6. 2,036,053

7. 399,479

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1. -

2. -

3. -

4. -

5. -

6. -

7. -

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1. 7,900

2. -

3. 114,950

4. 183,440

5. 44,015

6. 70,304

7. -

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1. 560,915

2. 31,405

3. 2,660,309

4. 281,146

5. 683,238

6. 1,965,749

7. 399,479

 

Name of contact:

Laura Taylor, Investor Relations

Telephone number of contact:

01223 696000

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

Laura Taylor, Investor Relations Manager

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Adviser

Peel Hunt LLP - Joint Corporate Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

Brunswick

+44 (0) 20 7404 5959

Justine Mcllroy / Will Medvei / Anna Carruth

 

Notes to Editors

 

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRGCGDDCDGBGUL
Date   Source Headline
16th Sep 20198:02 amRNSDirector/PDMR Shareholding
12th Sep 20197:00 amRNSNotice of Capital Markets Event
11th Sep 201910:33 amRNSDirector/PDMR Shareholding
11th Sep 201910:11 amRNSReplacement: Director/PDMR Shareholding
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 20197:00 amRNSFull year results for 12 months ended 30 June 2019
2nd Sep 20193:14 pmRNSTotal Voting Rights
1st Aug 201912:10 pmRNSTotal Voting Rights
22nd Jul 20197:01 amRNSDirectorate Change
22nd Jul 20197:00 amRNSFull Year Trading Update
16th Jul 20197:00 amRNSAcquisition of Cell Lines and Lysates Portfolio
1st Jul 20199:38 amRNSTotal Voting Rights
3rd Jun 201910:45 amRNSTotal Voting Rights
2nd May 201912:53 pmRNSTotal Voting Rights
1st May 20197:00 amRNSAppointment of Joint Broker
2nd Apr 20191:13 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSCompany Secretary Change
12th Mar 20197:00 amRNSHolding(s) in Company
8th Mar 20198:57 amRNSHolding(s) in Company
4th Mar 20197:00 amRNSInterim results for six months ended 31 Dec 2018
1st Mar 201910:29 amRNSTotal Voting Rights
25th Feb 20195:39 pmRNSChange of Registered Office
18th Feb 20191:01 pmRNSBlock listing Interim Review
5th Feb 201911:34 amRNSTotal Voting Rights
28th Jan 20197:00 amRNSAcquisition of Calico Biolabs
8th Jan 20197:00 amRNSHalf Year Trading Update
3rd Jan 20191:45 pmRNSTotal Voting Rights
3rd Jan 20197:00 amRNSAbcam to present at J.P. Morgan Conference
13th Dec 201810:06 amRNSDirectorate Change
6th Dec 20181:06 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:02 pmRNSDirector/PDMR Shareholding
3rd Dec 201812:21 pmRNSTotal Voting Rights
12th Nov 20181:59 pmRNSDirector/PDMR Shareholding
8th Nov 20189:32 amRNSDirector/PDMR Shareholding
6th Nov 20185:47 pmRNSResult of AGM
2nd Nov 20188:51 amRNSTotal Voting Rights
1st Nov 20181:22 pmRNSHolding(s) in Company
29th Oct 20188:57 amRNSDirector/PDMR Shareholding
10th Oct 201810:46 amRNSHolding(s) in Company
9th Oct 20188:59 amRNSDirector/PDMR Shareholding
2nd Oct 201812:54 pmRNSHolding(s) in Company
2nd Oct 201812:51 pmRNSDirector/PDMR Shareholding
1st Oct 20185:41 pmRNSTotal Voting Rights
28th Sep 201810:11 amRNSDirector/PDMR Shareholding
24th Sep 20182:42 pmRNSHolding(s) in Company
21st Sep 201812:56 pmRNSAnnual Financial Report
14th Sep 20189:46 amRNSDirector/PDMR Shareholding
13th Sep 20181:34 pmRNSDirector/PDMR Shareholding
13th Sep 20181:33 pmRNSDirector/PDMR Shareholding
11th Sep 201810:30 amRNSDividend Payment Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.